Clinical Trial Update: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating darovasertib (IDE196) as neoadjuvant/adjuvant therapy for localized uveal melanoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Darovasertib (darovasertib)

Snippet

Sponsor: IDEAYA Biosciences | Conditions: Uveal Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING